BridgeBio Pharma Inc Cash Flow-to-Debt Ratio
BridgeBio Pharma Inc cash flow-to-debt ratio. BridgeBio Pharma Inc (BBIO) has a Cash Flow-to-Debt Ratio of -0.02x as of June 2026, meaning its operating cash flow of $-71.10 Million could theoretically repay 0% of its total liabilities ($3.72 Billion) in one year. See how financially flexible is BridgeBio Pharma Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BridgeBio Pharma Inc (2017–2025)
Cash flow-to-debt ratio of BridgeBio Pharma Inc from 2017 to 2025. Historical debt coverage capacity for BridgeBio Pharma Inc across 9 annual periods. Check BridgeBio Pharma Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
BridgeBio Pharma Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
BridgeBio Pharma Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for BridgeBio Pharma Inc. For the full cash flow conversion analysis, see BBIO cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.15x | $-445.91 Million | $3.01 Billion | ▲ +32.4% |
| 2024 | -0.22x | $-520.73 Million | $2.38 Billion | ▲ +21.6% |
| 2023 | -0.28x | $-527.72 Million | $1.89 Billion | ▼ -24.4% |
| 2022 | -0.22x | $-419.49 Million | $1.87 Billion | ▲ +15.3% |
| 2021 | -0.27x | $-497.93 Million | $1.88 Billion | ▲ +60.5% |
| 2020 | -0.67x | $-399.71 Million | $595.70 Million | ▲ +58.8% |
| 2019 | -1.63x | $-253.59 Million | $155.70 Million | ▼ -575.1% |
| 2018 | -0.24x | $-136.64 Million | $566.44 Million | ▲ +9.0% |
| 2017 | -0.27x | $-40.49 Million | $152.73 Million | — |